VisageX Medical specializes in developing adjustable facial implants tailored for the aesthetics and reconstructive surgery market.
What sets us apart is our unique technology, allowing for the modification of implant shape and size long after the surgery is complete.
Our first-in-human study is scheduled for 2024.
The global market for facial plastic and reconstructive implants is projected to reach $1.6 billion by 2033, with a compound annual growth rate (CAGR) of 7.8%. VisageX holds a substantial competitive advantage, as there are currently no direct competitors offering a comparable product solution. We anticipate that our technology will significantly alter patient treatment paradigms, attracting increased adoption